SpinaFX Medical Inc – Weekly Recap

SpinaFX Medical Inc is a spine-focused medtech company developing minimally invasive, image-guided therapies for contained herniated discs, and this weekly recap reviews its latest clinical and regulatory progress. During the week, the company’s flagship Triojection intra-discal oxygen ozone injection therapy, which holds FDA Breakthrough Device designation, was a central focus at the American Society of Spine Radiology 2026 meeting.

At the ASSR 2026 symposium in New Orleans, SpinaFX leadership, including its medical, strategy, and clinical affairs executives, met directly with spine radiologists and interventional specialists. Their goal was to strengthen clinical credibility, deepen relationships with key opinion leaders, and position Triojection for eventual adoption in routine practice.

A hands-on workshop on February 25 showcased C-arm guided needle placement techniques and practical aspects of the Triojection procedure. Attendees reviewed clinical evidence, patient selection criteria, and follow-up protocols, signaling growing physician engagement and interest in image-guided back pain interventions.

Across multiple communications, SpinaFX highlighted that Triojection has received FDA Breakthrough Device designation and is moving toward more advanced clinical development. The company outlined plans for an Investigational Device Exemption trial, targeting patient enrollment in the second half of 2026, along with a pivotal study to generate robust safety and effectiveness data.

These planned trials are expected to support future regulatory review and reimbursement discussions by providing higher-quality clinical evidence. While no new approvals or commercial launches were announced, the regulatory momentum and trial planning mark a meaningful step toward potential commercialization of Triojection.

SpinaFX also emphasized its engagement with a broad network of clinicians and community partners during the ASSR26 meeting. These relationships could help facilitate trial enrollment, refine clinical protocols, and support future market uptake as minimally invasive spine care solutions gain wider attention.

Overall, the week reflected steady, strategically important progress for SpinaFX Medical Inc, as it combined specialty conference visibility, clinician education, and clinical trial preparation to advance its breakthrough-designated spine therapy toward potential market entry.